Lichen planopilaris treated by the peroxisome proliferator activated receptor-γ agonist pioglitazone: lack of lasting improvement or cure in the majority of patients

J Am Acad Dermatol. 2013 Nov;69(5):830-832. doi: 10.1016/j.jaad.2013.04.066.

Authors

Philipp Spring¹, Zoi Spanou², Pierre A de Viragh³

Affiliations

¹ Dermatology University Clinic, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
² Dermatology University Clinic, Inselspital, Bern, Switzerland.
³ Dermatology University Clinic, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; Dermatology University Clinic, Inselspital, Bern, Switzerland; Private practice, Zurich, Switzerland. Electronic address: [email protected].

PMID: 24124823
DOI: 10.1016/j.jaad.2013.04.066

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Female
Humans
Lichen Planus / drug therapy*
Male
Middle Aged
PPAR gamma / agonists*
Pioglitazone
Prospective Studies
Thiazolidinediones / therapeutic use*
Time Factors
Treatment Failure
Young Adult

Substances

PPAR gamma
Thiazolidinediones
Pioglitazone

Supplementary concepts

Lichen planus follicularis